| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
At a GI50 of 83 nM, MI-538 suppresses the growth of MLL leukemia cells. MI-538 demonstrated strong selectivity for MLL fusion protein-transformed cells, as evidenced by its lack of effect (up to 6 μM) on the development of control cell lines HL-60 and HM-2 lacking MLL translocation. MI-538 exhibits a modest nanomolar affinity (Kd=6.5 nM) for menin. greater binding affinity to menin and potentially greater permeability of the cell membrane are the causes of its strong cellular activity. Hoxa9 and Meis1 gene expression were significantly downregulated after receiving MI-538 therapy. In MLL-AF9 cells, Hoxa9 expression may be reduced by roughly 50% at a concentration of 100 nM 27, and the impact on Meis1 expression is more pronounced [1].
|
|---|---|
| ln Vivo |
MI-538 therapy led to a notable 80% reduction in MV4;11 tumor volume with less than 10% weight loss. The results of MI-538 showed a considerable improvement in minimum clearance, Cmax (maximum compound concentration) in plasma, and exposure (area under the curve, AUC, value). MI-538 has a half-life of about 1.6 hours. Moreover, MI-538 has a high oral bioavailability of around 50% [1].
|
| References |
| Molecular Formula |
C27H25F3N8OS
|
|---|---|
| Molecular Weight |
566.60
|
| Exact Mass |
566.182
|
| CAS # |
1857417-10-7
|
| PubChem CID |
117636625
|
| Appearance |
White to off-white solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
40
|
| Complexity |
914
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(CC2=CNN=C2)C2=C(C=C(CN3CCC(NC4N=CN=C5SC(CC(F)(F)F)=CC5=4)CC3)C(O)=C2)C=C1C#N
|
| InChi Key |
QXLJOBRSTCFLMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H25F3N8OS/c28-27(29,30)9-21-7-22-25(32-15-33-26(22)40-21)36-19-1-3-37(4-2-19)14-18-5-17-6-20(10-31)38(23(17)8-24(18)39)13-16-11-34-35-12-16/h5-8,11-12,15,19,39H,1-4,9,13-14H2,(H,34,35)(H,32,33,36)
|
| Chemical Name |
6-hydroxy-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]indole-2-carbonitrile
|
| Synonyms |
MI538; MI 538; MI-538
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~176.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (17.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (17.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 2.08 mg/mL (3.67 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7649 mL | 8.8246 mL | 17.6491 mL | |
| 5 mM | 0.3530 mL | 1.7649 mL | 3.5298 mL | |
| 10 mM | 0.1765 mL | 0.8825 mL | 1.7649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
